Exercise limitation is a cardinal feature of the interstitial lung diseases and is frequently associated with marked dyspnoea on exertion. People with interstitial lung disease exhibit a rapid, shallow breathing pattern during exercise that worsens as disease progresses. Despite this, ventilatory mechanics are not the major limitation to exercise in most patients, with impaired gas exchange and circulatory limitation playing a more important role. Peripheral and respiratory muscle dysfunction may also contribute to impaired exercise tolerance, either due to systemic manifestations of the underlying disease, treatment side-effects or deconditioning. Measures of exercise capacity or desaturation obtained from maximal and submaximal exercise tests are good predictors of survival in patients with idiopathic pulmonary fibrosis. However, to date few pharmaceutical treatments have affected exercise outcomes despite improvements in other important clinical markers. Supplemental oxygen acutely improves exercise capacity in interstitial lung disease and is recommended for hypoxic patients, although quality of life or survival benefits have not yet been demonstrated. Exercise training improves walking capacity and dyspnoea in short-term trials and is useful to maximize functional capacity. The role of exercise testing in the routine management of patients with interstitial lung disease is not clearly defined. However, given the poor prognosis in patients with idiopathic pulmonary fibrosis and the marked variation in clinical course, assessment of exercise capacity may provide useful information for both clinicians and patients when evaluating the risks and benefits of new treatments. The extent of resting or exercise-induced hypoxia in patients with interstitial lung disease may influence the selection of an appropriate exercise test, and oxygen administration should be standardized on repeat testing.
Introduction
The interstitial lung diseases (ILDs) are a diverse group of lung disorders that share common physiologic abnormalities and clinical characteristics. Exercise intolerance is a cardinal feature of the ILDs and is often associated with significant exertional dyspnoea and fatigue that may progress over time. Those patients with the worst exercise tolerance also have the worst quality of life. 1 Exercise limitation thus has a profound effect on the lives of patients with ILD and is an important problem for clinicians. The purpose of this review is to examine the mechanisms of exercise limitation in ILD, to summarize the relationship between exercise limitation and prognosis, and to examine therapeutic options to improve exercise tolerance in patients with ILD.
Mechanisms of exercise limitation in ILD
People with ILD exhibit a rapid, shallow breathing pattern that is present at rest and worsens during exercise. [2] [3] [4] This contrasts with the response in people without lung disease, where increased ventilatory demand gives rise to an increased tidal volume during mild-to-moderate exercise. The small tidal volume and rapid respiratory rate seen in people with ILD is thought to occur secondarily to inspiratory elastic loading, in order to reduce the respiratory forces required to maintain ventilation with poorly compliant lung tissue. Rapid, shallow breathing is more pronounced in those with more severe disease. 4 Despite this abnormal ventilatory pattern, respiratory mechanics are not thought to be the major contributor to exercise limitation in most patients. In two studies of ILD patients with varying diagnoses, most participants had a large ventilatory reserve at the end of exercise despite reduced exercise performance. 5, 6 Addition of oxygen and external dead space increased both exercise performance and minute ventilation, 7 suggesting that factors other than ventilatory mechanics are the major limitation to maximal exercise performance in this patient group. Impairment of gas exchange and circulatory limitation also play important roles in exercise limitation for people with ILD. Impaired gas exchange occurs as a result of destruction of the pulmonary capillary bed or thickening of the alveolarÀcapillary membrane, resulting in ventila-tionÀperfusion (V/Q) mismatch, oxygen diffusion limitation and low mixed venous partial pressure of oxygen (PO 2 ). 8 Impressive desaturation is frequently seen on both maximal and submaximal exercise tests, especially in patients with idiopathic pulmonary fibrosis (IPF). 9, 10 VentilationÀperfusion inequality is the primary contributor to arterial hypoxaemia at rest and during exercise; however, diffusion limitation also has an important role, contributing 19% to the alveo-larÀarterial oxygen pressure difference [P(A-a)O 2 ] at rest and rising to 40% during exercise. Those patients with more severe resting diffusion limitation have greater diffusion limitation during exercise. 8 The relationship between degree of impairment in diffusing capacity and exercise-induced hypoxaemia has been confirmed in patients with ILD of various aetiologies including IPF, asbestosis and sarcoidosis. [11] [12] [13] However, there may also be differences in the pattern and severity of gas exchange disturbance during exercise, which are attributable to diagnosis. Patients with IPF show a larger increase in P(A-a)O 2 during exercise than those with sarcoidosis 12 or asbestosis. 11 There may be more derangement in oxygen transport on exertion in patients whose disease is characterized by a greater degree of interstitial fibrosis, such as is seen in IPF. This hypothesis is supported by the relationships between exerciseinduced desaturation and the profusion and extent of parenchymal abnormality on imaging. 14, 15 Circulatory limitation also plays an important role in exercise limitation. In patients with ILD and a variety of diagnoses, the peak oxygen uptake (VO 2 ) correlated better with measures of circulatory impairment than with measures of ventilatory or gas exchange impairment. 6 Circulatory impairment was also the primary limitation to exercise in patients with systemic sclerosis and restrictive lung disease. 16 Circulatory limitation results from pulmonary capillary destruction and hypoxic pulmonary vasoconstriction, 8 leading to pulmonary hypertension and cardiac dysfunction in some patients. Different types of circulatory limitation are more important in different disease states. Pulmonary hypertension is common in patients with IPF and there is a strong relationship between elevation in pulmonary artery pressures and both maximal and submaximal exercise performance. 17, 18 An abnormal heart rate response to exercise has also been documented in IPF, 2 and this is associated with reduced oxygen dispatch to the tissues. 19 Cardiac dysfunction has been documented during exercise in patients with sarcoidosis, often in patients without overt signs of cardiac involvement, lung function impairment or oxygen desaturation. 20 This may represent subclinical granulomatous infiltration of the myocardium.
Peripheral muscle dysfunction is emerging as an important contributor to exercise limitation in ILD. In 41 patients with IPF, who were diagnosed according to the international consensus statement, quadriceps muscle torque was reduced to a mean of 65% of the predicted value. 21 Quadriceps force was an independent predictor of VO 2 peak, along with vital capacity and ventilatory equivalent for CO 2 at endexercise. A similar relationship between quadriceps peak torque and both peak workload and functional exercise capacity has been documented in patients with sarcoidosis, who reported fatigue. 22 The mean value of quadriceps peak torque was 67% predicted and was inversely related to the mean daily dose of corticosteroids received in the 6 months before testing. Respiratory muscle strength may also have an impact on exercise performance. In sarcoidosis patients with no signs of skeletal muscle involvement, twitch mouth pressure during inspiration was a stronger predictor of the 6-minute walk distance (6MWD) than respiratory function tests or oxygenation. 23 .
Although proximal skeletal muscle weakness is a well-known manifestation of sarcoidosis, less is known about the potential impact and mechanisms of skeletal muscle dysfunction in other ILDs. It is likely that physical deconditioning plays a similar role in ILD as it does in other chronic lung diseases, with avoidance of activities that provoke dyspnoea leading to a vicious cycle of worsening exercise capacity and increasing symptoms. There may also be systemic effects of diseases such as IPF that are yet to be defined. Corticosteroid treatment may contribute to myopathy of peripheral and respiratory muscles, although findings are inconsistent. 22, 23 Given the potential for deleterious effects of treatment on skeletal muscle, more information is needed regarding the impact of skeletal muscle function on clinical outcome.
Exercise limitation as a marker of prognosis
Exercise challenges the respiratory, cardiovascular and neuromuscular systems. Measures of exercise limitation therefore provide an integrated assessment of contributors to functional limitation and disease progression in ILD. A number of authors have found strong relationships between exercise test performance and mortality, particularly in patients with IPF (Table 1 ). Exercise variables are frequently stronger predictors of prognosis than resting lung function, 25, 32 although there is no consensus regarding which exercise variable best predicts long-term outcome. Measures of exercise capacity and exercise-induced hypoxaemia, obtained on maximal or submaximal exercise tests, have been linked to prognosis.
Cardiopulmonary exercise testing: Peak oxygen uptake has been linked to survival in patients with diffuse parenchymal lung disease (DPLD) referred for lung transplant assessment 26 and in patients with IPF diagnosed according to the consensus statement. 25, 27 Those patients with a VO 2 peak less than 8.3 mL.kg.min À1 had a threefold greater hazard of dying during follow-up after adjusting for baseline lung function, age, gender and smoking status. 27 Gas exchange measures during cardiopulmonary exercise test (CPET) have also been linked to mortality, although these results are less consistent. The partial pressure of oxygen in arterial blood (PaO 2 ) at maximum exercise predicts survival and contributes up to 10.5% of the total clinical, radiographic and physiologic (CRP) score, a composite scoring system that is used to assess prognosis. 24 Whilst some authors have confirmed a relationship between exerciseinduced hypoxia on CPET and mortality, 9, 25 other studies have failed to document such an association. 35, 36 Exercise arterial blood gas measurements are not available in all settings and given the lack of consensus in the literature regarding their importance, the VO2 peak may provide a more useful estimate of prognosis.
Field tests of exercise capacity: The 6-minute walk test is increasingly used to assess prognosis in patients with IPF. In patients with severe IPF who were awaiting lung transplantation, a 6MWD less than 207 m was associated with a fourfold increase in mortality rate. 29 A similar threshold was identified in unselected patients with IPF diagnosed according to the consensus statement. 30 However, others have not found a relationship between distance walked and mortality. 10, 32 Desaturation on 6-minute walk test may be a more powerful indicator of prognosis. Various markers of desaturation have been linked to increased risk of mortality, including change in oxyhaemoglobin saturation (SpO 2 ) during the test, 25,33 a threshold value of SpO2 88%, 10,25 the distanceÀ saturation product (distance Â nadir SpO 2 ) 31 and desaturation area (total area above the desaturation curve using values calculated at each minute of the test). 32 A threshold of SpO 2 88% appears more reliable than measures of desaturation that rely on absolute change. 24 However, recent data suggest that desaturation on 6MWT may be a less powerful a predictor of mortality than a VO 2 peak. 27 The ability to assess prognosis is important for both patients and clinicians. Although the poor outlook for patients with IPF is well recognized, there is significant variation between individuals in the clinical course. Many treatments for IPF involve weighing up the risks and benefits of new or experimental therapies. Information regarding likely prognosis can inform both patients and physicians when making these difficult decisions.
Interventions to improve exercise tolerance in ILD
Although exercise intolerance is a cardinal feature of ILDs, few treatments have been shown to improve exercise capacity. Exercise outcomes have been measured in trials of oxygen therapy, drugs and rehabilitation with inconsistent results.
Two studies have assessed the acute effects of oxygen therapy in patients with a variety of ILDs and moderate disease. 7, 37 Compared to exercise on room air, high flow oxygen (fraction of inspired oxygen [FiO 2 ] 0.60) substantially improved endurance time in both studies. The greatest gains were seen in patients who desaturated during exercise. 37 However, only one study found a significant effect of oxygen on VO 2 peak and maximum work rate. 7 All participants in this study desaturated on exercise, and it is likely that oxygen has more important effects in this group. To date, there have been no studies examining the longer-term effects of oxygen therapy on exercise capacity in patients with ILD and thus it is not known whether there are survival or quality-of-life benefits from oxygen therapy. 38 However, current guidelines recommend the prescription of long-term oxygen therapy for patients who are hypoxic at rest, especially if pulmonary hypertension is present. 39 Ambulatory oxygen is recommended for patients who desaturate to less than 90% during exercise if a clear beneficial effect on exercise capacity or dyspnoea is seen. 39 A number of randomized controlled trials have examined the effects of pharmaceutical treatments on exercise capacity in IPF; however, statistically significant outcomes are infrequently demonstrated and effect sizes are small ( Table 2 ). Small but non-significant changes in peak exercise capacity were found in a large placebo controlled trial of N-Acetylcysteine 38 . Bosentan did not improve 6MWD at 12 months compared to placebo, despite trends favouring the treatment group for time to death or disease progression, quality of life and dyspnoea. 41 Likewise, a large trial comparing pirfenidone to placebo did not find a difference in nadir oxygen saturation on a 6-minute treadmill test after 6 months, despite improvements in vital capacity and a reduced rate of acute exacerbation in the treatment group. 40 A pilot randomized controlled trial of oral co-trimoxazole in patients with poorly defined end-stage fibrotic lung disease showed significant improvements in the shuttle walk test and less exercise-induced desaturation after 3 months of treatment. 45 The mechanism for these improvements is not clear and the results need to be confirmed in a larger study. A small crossover trial evaluated the acute effects of low-dose nebulised morphine during an incremental exercise test in patients with ILD of various aetiologies. 46 No effects on dyspnoea or exercise capacity were evident.
There is increasing interest in the effects of rehabilitation for people with ILD. Two randomized controlled trials have found positive effects in 8-10 weeks of exercise training in samples with ILD of varying aetiology 43 or IPF only. 44 The improvement in 6MWD is smaller than that seen in patients with chronic obstructive pulmonary disease (COPD) following exercise training 47 and patients with IPF appear to have smaller gains than those with ILD of other aetiology, 48 although the improved walking distance is still associated with significant improvement in health-related quality of life. Exercise training also reduces dyspnoea; however, no change in VO 2 peak has been documented. 43 It appears that exercise training is beneficial across the spectrum of disease although improvements may be harder to identify in those with better preserved 6MWD at program entry. 49 Only one study to date has evaluated longer term effects of exercise training and was unable to document any ongoing benefits at 6 months. 43 Despite this, it is recommended that all patients with ILD have access to a local pulmonary rehabilitation programme to ensure that functional capacity is maximized. 39 The failure of modern therapies to affect long-term exercise outcomes in ILD, even in trials where other outcomes improve, is disappointing. Given the strong relationship between exercise capacity and survival, as well as the impact of exercise intolerance on patients' lives, treatments that improve this outcome are highly desirable. It is possible that currently used tests of exercise capacity are not sensitive enough to detect subtle changes in cardiopulmonary variables that occur following treatment. Some variables measured during exercise testing, particularly degree of desaturation, may be too variable to reliably detect change. 25 The contribution of peripheral muscle performance to exercise capacity, a variable not altered by most pharmaceutical treatments in patients with chronic disease, may also limit the ability of pharmacotherapy to change exercise outcomes. Given the promising effects of exercise training, the addition of pulmonary rehabilitation programmes to drug treatment trials may be a fruitful area for exploration.
When should we assess exercise capacity in ILD?
Cardiopulmonary exercise testing is frequently used to aid in the diagnosis of ILD. Abnormal responses such as exercise-induced hypoxia and excessive ventilation may be evident despite normal respiratory function at rest, providing clues to early disease. In patients with sarcoidosis, who had normal spirometry and TLCO, over half had abnormal ventilatory responses to exercise. 50 suggesting abnormalities in ventilationÀperfusion matching that are not evident under resting conditions. In a study of 42 patients with ILD of varying aetiologies, 14% had an abnormal CPET despite normal resting pulmonary function. 6 Although a CPET is very sensitive in detecting changes in physiology characteristic of ILD, these findings are not diagnostic. Given that the high-resolution computed tomography (HRCT) now plays a large role in diagnosis, the importance of the CPET is less clear. Current guidelines suggest that a CPET is most useful when normal, to exclude clinically important ILD in patients with normal radiology and pulmonary function. 39 Exercise tests may have a role in staging and monitoring disease; however, this has not been clearly defined. Exercise-induced changes in oxygenation during both maximal and submaximal tests have been associated with extent of ILD on biopsy and imaging, [52] [53] [54] indicating a relationship with disease severity. However, in patients with IPF, disease severity and progression can be effectively evaluated using spirometry and TLCO with 6 months' follow-up. [55] [56] [57] Current guidelines indicate that routine exercise testing does not add to these measures for patients with IPF. 39 However, exercise tests provide a global evaluation of functional capacity and this may be particularly relevant for ILDs with peripheral or respiratory muscle involvement, or where increased symptoms are not explained by changes in respiratory function variables.
Serial exercise tests should be considered where patients and clinicians require updated information about prognosis, or to evaluate the response to a new therapy. In patients who did not desaturate on the 6minute walk test at baseline, increased oxygen desaturation on a repeat test at 6 months was associated with a twofold greater hazard of dying during follow-up in patients with IPF. 32 The value of serial CPETs has not been studied. It is recommended that submaximal exercise testing be considered before commencing a new treatment, 39 despite the few treatments that have impacted on this outcome (Table 2) . However, changes in the 6MWD are strongly related to patients' assessments of clinically important change. 58 This suggests that changes in the 6-minute walk test may assist in assessing the costs and benefits of new therapies to individual patients.
Considerations for exercise testing in ILD
The choice of an exercise test will be determined by the purpose of testing, the measurement properties of the test and the individual patient characteristics. The CPET and the 6-minute walk test are the most commonly used exercise tests in ILD. While the CPET is frequently used to assist diagnosis, the 6minute walk test is more commonly used to monitor progress over time. Both have a clear relationship to clinically important outcomes (Table 1 ) and both exhibit good measurement properties. The reproducibility of VO 2 peak measurements obtained from CPET is fair in IPF, with a correlation coefficient of .88. 25 The distance walked in 6 min is highly reproducible in patients with IPF 25 and systemic sclerosis, 59 with between-test correlation coefficients of .98 and .95, respectively. There appears to be a small learning effect for the 6-minute walk test, with a mean increase of 20 m between first and second tests. 59 Although this increase is unlikely to be clinically significant on one testing occasion, it may be important if the test is to be used to evaluate change over time. The extent of oxygen desaturation on both 6-minute walk test and CPET is less reproducible than measures of exercise capacity, exhibiting major variation between testing occasions. 25 The use of a clinically significant threshold value, such as SpO 2 88%, may give a more reliable estimate of whether important exertional desaturation has taken place. The CPET may not be available outside major centres due to equipment and financial constraints. The 6-minute walk test is a meaningful alternative but has substantial space requirements due to the need for a 30-m corridor. 60 Other exercise tests whose use has been reported in ILD include the incremental shuttle walk test, 61 4-min and 6-min step tests 34, 62 and the 6-min treadmill test. 40 Distance walked on the incremental shuttle walk test has a strong relationship to VO 2 peak in patients with IPF 61 and this test may also be responsive to therapy. 45 However, the relationship of incremental shuttle walk distance to clinical progression and mortality has not been tested. Self-paced step tests lasting 4 min 34 or 6 min 62 have been used to evaluate exercise-induced desaturation in single studies of patients with IPF, and relationships to VO 2 peak and mortality have been demonstrated. These tests have the advantage of minimal space and equipment requirements; however, at present there is no standardized protocol for their administration. Desaturation on a 6-min treadmill walking test was responsive to treatment in one trial 40 ; however, little is known regarding its measurement properties in patients with ILD. These tests may have application in settings where the CPET or the 6-min walk test cannot be performed due to equipment or space restrictions.
The extent of resting and exercise-induced hypoxia in patients with ILD may influence test selection and require modification to usual testing protocols. Up to 30% of patients with severe ILD may be unable to perform a CPET due to resting hypoxia and the requirement that testing be performed without supplemental oxygen to allow measurement of VO 2 peak. 63 Many centres require that exercise tests are ceased when oxygen saturation falls below 80% for safety reasons, resulting in early termination of tests in some patients with ILD. Both maximal and submaximal tests can be difficult to interpret in these circumstances as a true estimate of exercise capacity is not attained. Supplemental oxygen may be used during field walking tests; however, given the acute effects of oxygen on exercise performance in ILD, 7, 37 its use should be standardized both within and between patients. A variation of the 6-min walk test, the timed walk test, 33 provides standardized criteria for administration of oxygen, test cessation and evaluation of test performance in hypoxic patients.
Oxygenation during exercise testing is commonly measured using pulse oximetry; however, this may be technically challenging in patients with poor digital perfusion, such as some patients with systemic sclerosis. 64 An ear probe may be required to obtain reliable estimates of oxyhaemoglobin saturation when a trace cannot be obtained from the digits, although this not often necessary. 28 Where a pulse oximetry trace can be obtained, it accurately reflects arterial oxyhaemoglobin saturation and an arterial line, with its attendant risks, is not required. 28 
Detecting change in exercise capacity over time for patients with ILD
Monitoring changes in exercise capacity over time requires an understanding of the magnitude of change that would be considered clinically significant. This is known as the minimal important difference (MID) and refers to the smallest change that patients and clinicians would consider important enough to warrant a change in treatment plan. 65 To date an MID for the CPET has not been identified in patients with ILD; however, some data are available to guide assessment of change in 6MWD. In a group of 48 patients with ILD (24 IPF) a change of 30 m in 6MWD was perceived as clinically important by both patients and clinicians. 58 Although the threshold was similar in the subgroup of patients with IPF, this short-term study did not include sufficient numbers of patients who deteriorated to assess whether the MID for worsening was different to that for improvement. Further work is required to identify clinically relevant thresholds for change in exercise capacity in people with ILD.
Conclusion
Exercise intolerance is an important feature of ILD that is associated with poor quality of life and closely linked to mortality. Assessment of exercise capacity may assist with diagnosis, particularly in patients where symptoms are not consistent with resting physiology. Exercise testing may also provide useful information about likely prognosis, particularly in IPF, which may assist patients and clinicians when facing difficult treatment decisions. Few treatments have significantly impacted on exercise capacity in ILD, although pulmonary rehabilitation results in short-term improvements. New therapies that have an impact on exercise tolerance in ILD are eagerly awaited.
